30.04.2018
Heidelberg Pharma AG DE000A11QVV0
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Presents at Upcoming Conferences and Investor Events
DGAP-News: Heidelberg Pharma AG / Key word(s): Conference
Heidelberg Pharma AG: Heidelberg Pharma Presents at Upcoming Conferences and
Investor Events
30.04.2018 / 11:32
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Heidelberg Pharma Presents at Upcoming Conferences and Investor Events
Ladenburg, Germany, 30 April 2018 - Heidelberg Pharma AG (FSE: WL6) today
announced that they will participate at upcoming conferences and investor
events, and present the company as well as their proprietary ATAC technology
platform. Heidelberg Pharma's management will be available for one-on-one
meetings at these events.
14th Annual PEGS: The Essential Protein Engineering Summit
Date: 30 April - 04 May 2018
Venue: Seaport World Trade Center, Boston, USA
Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, will
present the following speech on Wednesday, 02 May 2018 at 09:10 a.m. EDT:
Antibody Targeted Amanitin Conjugates (ATACs) - Expanding the ADC landscape
with a new payload targeting RNA Polymerase II
Non Deal Roadshow USA
07 - 08 May 2018: New York
09 - 10 May 2018: Boston
BioEquity Europe 2018
Date: 14 - 16 May 2018
Venue: Het Pand Conference Center, Ghent, Belgium
Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer
of Heidelberg Pharma, will hold a company presentation on Tuesday, 15 May
2018 at 06.00 p.m. CEST.
About Heidelberg Pharma's proprietary ATAC technology
Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of
antibodies with the potency of cytotoxic small molecules for the treatment
of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose
active ingredient is made up of amatoxin molecules. Amatoxins are small
bicyclic peptides naturally occurring in the death cap mushroom. They
inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that
is crucial for the survival of eukaryotic cells. In preclinical testing,
ATACs have been shown to be highly efficacious, overcoming frequently
encountered resistance mechanisms and combating even quiescent tumor cells.
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg,
Germany. Heidelberg Pharma is an oncology specialist and the first company
to develop the toxin Amanitin into cancer therapies using its proprietary
Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the
biological mode of action of the toxin as a novel therapeutic principle.
This proprietary technology platform is being applied to develop the
Company's proprietary therapeutic ATACs, as well as in third-party
collaborations, to create a variety of ATAC candidates. The proprietary lead
candidate is HDP-101, a BCMA ATAC for multiple myeloma.
The Company has entered into partnerships to further develop and
commercialize its clinical assets MESUPRON(R) and REDECTANE(R), while
RENCAREX(R) is available for out-licensing and further development.
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
www.heidelberg-pharma.com.
Contact Heidelberg Pharma AG IR/PR support MC Services AG
Corporate Communications Sylvia Katja Arnold (CIRO) Managing
Wimmer Tel.: +49 89 41 31 38-29 Director & Partner Tel.: +49 89
E-Mail: investors[at]hdpharma.com 210 228-40 Mobil: +49 160 9360
Schriesheimer Str. 101, 68526 3022 E-Mail:
Ladenburg katja.arnold[at]mc-services.eu
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to place
undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
---------------------------------------------------------------------------
30.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: [email protected]
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
680785 30.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Heidelberg Pharma AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6